Coronavirus disease (Covid-19) is characterized by an intense inflammatory response and coagulopathy that is associated to a high incidence of thrombotic events with in situ thrombosis of the microcirculation of the lungs and other organs, which is the key event in the pathogenesis of the respiratory and multi-organ failure. These observations have led to to the use of heparin, which has anticoagulant, antiinflammatory and anti-viral properties, as the best agent to treat these patients. Clinical guidelines recommend the use of heparin thromboprophilaxis in these patients, although there is no agreement in the indication, dose and duration of thromboprophylaxis due to lack of randomized studies.
Samaniego E, F., & Conte L., G. (2020). Recomendaciones de prevención y tratamiento de tromboembolismo venoso en infección por SARS-CoV-2. Revista Hospital Clínico Universidad De Chile, 31(3), pp. 198–205. https://doi.org/10.5354/2735-7996.2020.69835
